Piracetam is most commonly used for breath-holding attacks, seizure disorder (epilepsy), dizziness (vertigo), a learning disorder marked by difficulty reading (dyslexia), and a movement disorder often caused by antipsychotic drugs (tardive dyskinesia). It is also used for dementia, schizophrenia, sickle cell disease, and many other conditions, but there is no good scientific evidence to support many of these uses.
How does it work ?
Uses & Effectiveness ?
Possibly Effective for
- Breath-holding attacks. Some research shows that taking piracetam for 2-3 months helps to reduce breath-holding spells in young children.
- Surgery to improve blood flow to the heart (CABG surgery). Most available research shows that giving a single dose of piracetam by injection (IV) or by mouth around the time of CABG surgery helps with memory recall after surgery.
- A learning disorder marked by difficulty reading (dyslexia). Most early research shows that taking piracetam for at least 12 weeks improves some reading skills in children aged 7-14 years with dyslexia.
- Seizure disorder (epilepsy). Most available research shows that taking piracetam reduces some symptoms of epilepsy in some patients who are also taking antiseizure drugs. But not all research agrees on which symptoms are improved by piracetam.
- A movement disorder often caused by antipsychotic drugs (tardive dyskinesia). Some research shows that symptoms of tardive dyskinesia improve in some people when piracetam is taken by mouth or given with a needle.
- Dizziness (vertigo). Some research shows that giving piracetam intravenously (by IV) decreases feelings of dizziness in people with vertigo. Taking piracetam by mouth for one week also seems to be helpful for reducing vertigo symptoms in people with acute vertigo. In people with chronic vertigo, taking piracetam by mouth might reduce the number of vertigo spells. But it doesn't seem to make the spells less severe.
Insufficient Evidence for
- Alzheimer disease. Early research shows that taking piracetam does not improve mental function in people with Alzheimer disease.
- Decline in memory and thinking skills that occurs normally with age. Early research shows that taking piracetam three times daily might improve memory loss with aging in some people.
- Autism. Early research shows that taking piracetam with a medication called risperidone helps improve some symptoms of autism in children.
- Cocaine use disorder. Early research shows that taking piracetam does not help with cocaine addiction. In some people, it might even increase cocaine use.
- Dementia. Early research shows that taking piracetam might improve memory loss in some patients with dementia.
- Down syndrome. Early research shows that taking piracetam does not help children with Down syndrome. In some children, aggression and irritability might increase.
- Memory. Early research shows that taking piracetam does not improve memory loss in people who have had electroconvulsive therapy (ECT).
- Parkinson disease. Early research shows that taking piracetam does not improve symptoms of Parkinson disease.
- Recovery after surgery. Early research shows that giving a single dose of piracetam by injection (IV) does not improve memory in people who have had open heart surgery.
- Schizophrenia. Early research shows that taking piracetam with a medication called haloperidol reduces some symptoms of schizophrenia. But it's not clear if it is beneficial when taken with the newer, more effective drugs used for schizophrenia.
- Sickle cell disease. Some early research shows that taking piracetam might reduce the severity of symptoms in children with sickle cell disease. However, not all research agrees. Doctors do not recommend piracetam for sickle cell disease.
- Stroke. Some early research shows that taking piracetam might prevent a second stroke. One study also shows that certain groups of people with a stroke might benefit more from piracetam than others. But overall, piracetam doesn't seem to prevent death, improve function, or improve speaking ability following a stroke. In fact, piracetam might increase the risk for death in patients with the most severe symptoms of stroke.
- Hearing loss.
- Other uses.
When given by IV: Piracetam is POSSIBLY SAFE when given by IV by a healthcare professional.
Special Precautions and Warnings
Children: Piracetam is POSSIBLY SAFE when taken by mouth under the supervision of a medical professional.
Cocaine use disorder: Piracetam seems to increase cocaine use in people who are addicted to cocaine and are trying to quit. Until more is known, do not use piracetam if you have cocaine use disorder.
Epilepsy: Stopping piracetam or decreasing the dose of piracetam might increase the number of seizures in people with epilepsy. If you have epilepsy, use piracetam only under the care of a doctor.
Huntington disease: Piracetam seems to increase symptoms in people with Huntington disease. Until more is known, do not use piracetam if you have Huntington disease.
Kidney problems: Piracetam is removed from the body by the kidneys. Talk to a healthcare provider before using piracetam if you have kidney problems.
Surgery: Piracetam might slow blood clotting. This might result in too much bleeding if it is used before surgery. Stop taking piracetam at least 2 weeks before surgery.
We currently have no information for PIRACETAM overview.
- For surgery to improve blood flow to the heart (CABG surgery): Piracetam 12 grams daily for 6 weeks, starting on day 6 after surgery.
- For seizure disorder (epilepsy): Piracetam 9.6-24 grams daily for up to 18 months.
- For a movement disorder often caused by antipsychotic drugs (tardive dyskinesia): Piracetam 2.4 grams twice daily for 4 weeks.
- For vertigo: Piracetam 800 mg three times daily for 1-8 weeks.
- For surgery to improve blood flow to the heart (CABG surgery): Piracetam 12 grams administered by a healthcare professional as a single dose. Piracetam 12 grams, administered by a healthcare professional daily from the day before surgery to 6 days after surgery.
- For a movement disorder often caused by antipsychotic drugs (tardive dyskinesia): Piracetam 8-24 grams daily administered by a healthcare professional.
- For vertigo: Piracetam 1-2 grams administered by a healthcare professional as a single dose.
- For breath-holding attacks: Piracetam 40 mg/kg daily for 2-3 months in children 6-36 months of age.
- For dyslexia: Piracetam 3.3 grams daily for at least 12 weeks in children aged 7-14 years.
Abbaskhanian A, Ehteshami S, Sajjadi S, Rezai MS. Effects of piracetam on pediatric breath holding spells: a randomized double blind controlled trial. Iran J Child Neurol. 2012;6(4):9-15. View abstract.
Ackerman PT, Dykman RA, Holloway C, et al. A trial of piracetam in two subgroups of students with dyslexia enrolled in summer tutoring. J Learn Disabil. 1991;24(9):542-9. View abstract.
Akhondzadeh S, Tajdar H, Mohammadi MR, et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev. 2008;39(3):237-45. View abstract
Al Hajeri A, Fedorowicz Z. Piracetam for reducing the incidence of painful sickle cell disease crises. Cochrane Database Syst Rev. 2016 Feb 12;2:CD006111. View abstract.
Arhami Dolatabadi A, Larimi SR, Safaie A. Oral piracetam vs betahistine in outpatient management of peripheral vertigo; a randomized clinical trial. Arch Acad Emerg Med. 2019;7(1):e9. View abstract.
Barkat K, Ahmad M, Minhas MU, et al. Development of a simple chromatographic method for the determination of piracetam in human plasma and its pharmacokinetic evaluation. Drug Res (Stuttg). 2014;64(7):384-8. View abstract.
Chen SY, Liu JW, Wang YH, et al. The conditions under which piracetam is used and the factors that can improve National Institute of Health stroke scale score in ischemic stroke patients and the importance of previously unnoticed factors from a hospital-based observational study in Taiwan. J Clin Med. 2019;8(1). pii: E122. View abstract.
Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon M. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology. 1993;43(2):301-5. View abstract.
De Reuck J, Van Vleymen B. The clinical safety of high-dose piracetam--its use in the treatment of acute stroke. Pharmacopsychiatry. 1999;32 Suppl 1:33-7. View abstract.
Di Ianni M, Wilsher CR, Blank MS, et al. The effects of piracetam in children with dyslexia. J Clin Psychopharmacol. 1985;5(5):272-8. View abstract.
Dogan NÖ, Avcu N, Yaka E, et al. Comparison of the therapeutic efficacy of intravenous dimenhydrinate and intravenous piracetam in patients with vertigo: a randomised clinical trial. Emerg Med J. 2015;32(7):520-4. View abstract.
Donma MM. Clinical efficacy of piracetam in treatment of breath-holding spells. Pediatr Neurol. 1998;18(1):41-5.
El-Hazmi MA, Al-Fawaz I, Warsy A, et al. Piracetam for the treatment of sickle cell disease in children- a double blind test. Saudi Med J. 1998;19(1):22-27. View abstract.
Fang Y, Qiu Z, Hu W, et al. Effect of piracetam on the cognitive performance of patients undergoing coronary bypass surgery: A meta-analysis. Exp Ther Med 2014;7(2):429-434. View abstract.
Fedi M, Reutens D, Dubeau F, et al. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 2001;58(5):781-6. View abstract.
Grotemeyer KH, Evers S, Fischer M, Husstedt IW. Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. J Neurol Sci. 2000;181(1-2):65-72. View abstract.
Holinski S, Claus B, Alaaraj N, et al. Cerebroprotective effect of piracetam in patients undergoing open heart surgery. Ann Thorac Cardiovasc Surg 2011;17(2):137-42. View abstract.
Hussain Y, Krishnamurthy S. Piracetam attenuates binge eating disorder related symptoms in rats. Pharmacol Biochem Behav. 2018;169:35-47. View abstract.
Kampman K, Majewska MD, Tourian K, et al. A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. Addict Behav 2003;28(3):437-48. View abstract.
Koskiniemi M, Van Vleymen B, Hakamies L, et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998;64(3):344-8. View abstract.
Libov I, Miodownik C, Bersudsky Y, et l. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007;68(7):1031-7. View abstract.
Lobaugh NJ, Karaskov V, Rombough V, et al. Piracetam therapy does not enhance cognitive functioning in children with down syndrome. Arch Pediatr Adolesc Med 2001;155(4):442-8. View abstract.
Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs 2010;70(3):287-312. View abstract.
Mateo D, Giménez-Roldán S. The effect of piracetam on involuntary movements in Huntington's disease. A double-blind, placebo-controlled study. Neurologia. 1996;11(1):16-9. View abstract.
May BH, Yang AW, Zhang AL, et al. Chinese herbal medicine for mild cognitive impairment and age associated memory impairment: a review of randomised controlled trials. Biogerontology 2009;10(2):109-23.
Mikati MA, Solh HM, Deryan DE, Sahli IF, Dabbous IA. A preliminary report on piracetam in sickle cell anemia: A double-blind crossover clinical trial and effects on erythrocyte survival. The King Faisal Spec Hosp J 1983;3:233-234.
Moriau M, Crasborn L, Lavenne-Pardonge E, et al. Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects. Arzneimittelforschung. 1993;43(2):110-8. View abstract.
Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol. 2009;39(3):311-21. View abstract.
Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther. 1999;24(5):369-74. View abstract.
Ozdemir H, Akinci E, Coskun F. Comparison of the effectiveness of intravenous piracetam and intravenous dimenhydrinate in the treatment of acute peripheral vertigo in the emergency department. Singapore Med J 2013;54(11):649-52. View abstract.
Psillas G, Pavlidis P, Karvelis I, et al. Potential efficacy of early treatment of acute acoustic trauma with steroids and piracetam after gunshot noise. Eur Arch Otorhinolaryngol. 2008;265(12):1465-9. View abstract.
Rameis H, Hitzenberger G, Kutscher R, Manigley C. Pharmacokinetics of piracetam: a study on the bioavailability with special regard to renal and non-renal elimination. Int J Clin Pharmacol Ther. 1994;32(9):458-65. View abstract.
Rao MG, Holla B, Varambally S, et al. Piracetam treatment in patients with cognitive impairment. Gen Hosp Psychiatry. 2013;35(4):451.e5-6. View abstract.
Ricci S, Celani MG, Cantisani TA, Righetti E. Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD000419. View abstract.
Rosenhall U, Deberdt W, Friberg U, Kerr A, Oosterveld W. Piracetam in patients with chronic vertigo. Clin. Drug Invest. 1996;11(5):251-60.
Sandyk R, Gillman MA. Piracetam causes confusion in a patient with temporal lobe epilepsy. J Am Geriatr Soc. 1985;33(4):305. View abstract.
Sano M, Stern Y, Marder K, Mayeux R. A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease. Mov Disord. 1990;5(3):230-4. View abstract.
Szalma I, Kiss A, Kardos L, et al. Piracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo. Ann Thorac Surg 2006;82(4):1430-5. View abstract.
Tang WK, Ungvari GS, Leung HC. Effect of piracetam on ECT-induced cognitive disturbances: a randomized, placebo-controlled, double-blind study. J ECT. 2002;18(3):130-7. View abstract.
Tuncer S, Sencan A, Aral M, Ayhan S. Piracetam-induced dysarthria: an unusual complication of antithrombotic prophylaxis after toe to finger transfer. J Reconstr Microsurg. 2011;27(9):575-6. View abstract.
Waegemans T, Wilsher CR, Danniau A, et al. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord 2002;13(4):217-24. View abstract.
Washington N, Harris M, Mussellwhite A, Spiller RC. Moderation of lactulose-induced diarrhea by psyllium: effects on motility and fermentation. Am J Clin Nutr 1998;67:317-21. View abstract.
Waters B, Resnick M, Simeon J, et al. An adverse reaction to piracetam in an hypothyroid 10 year old boy. Prog Neuropsychopharmacol. 1980;4(2):207-9. View abstract.
Wilsher CR, Bennett D, Chase CH, et al. Piracetam and dyslexia: effects on reading tests. J Clin Psychopharmacol 1987;7(4):230-7. View abstract.
Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169-82. View abstract.
Winnicka K, Tomasiak M, Bielawska A. Piracetam--an old drug with novel properties? Acta Pol Pharm. 2005;62(5):405-9. View abstract.
Yeo SH, Lim ZI, Mao J, Yau WP. Effects of Central Nervous System Drugs on Recovery After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig. 2017 Jul 29. View abstract.
Zhang J, Wei R, Chen Z, Luo B. Piracetam for aphasia in post-stroke patients: A systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2016;30(7):575-87. View abstract.
Select a condition to view a list of vitamins